Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4439685 | 1.00 | LMNA (0.44) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL6665040 | 1.00 | LMNA (0.44) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL17172093 | 0.94 | LMNA (0.41) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL4439683 | 0.92 | HCAR2 (0.50) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL8940099 | 0.92 | HCAR2 (0.50) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL8661906 | 0.92 | HCAR2 (0.50) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL16994445 | 0.90 | HCAR2 (0.50) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL17048417 | 0.90 | HCAR2 (0.50) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL17048229 | 0.90 | HCAR2 (0.50) | LMNAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL17048270 | 0.90 | HCAR2 (0.50) | LMNAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119235804-A | Carbamazepine pharmaceutical composition and preparation method and application thereof | 上海则正医药科技股份有限公司 | 2025-01-03 | — | — | CN | claimed |
| US-20240238206-A1 | LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2024-07-18 | — | — | US | claimed |
| CN-118055759-A | Miniature tablet containing losartan for pediatric use | 米达斯制药有限责任公司 | 2024-05-17 | — | — | CN | claimed |
| EP-4135668-B1 | SOLID ORAL DOSAGE FORM COMPRISING POMALIDOMIDE | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2024-04-17 | — | — | EP | claimed |
| EP-4333816-A1 | LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2024-03-13 | — | — | EP | claimed |
| CN-116947642-A | Long-residence polyalcohol hair care raw material molecule and preparation and application thereof | 江南大学 | 2023-10-27 | — | — | CN | claimed |
| WO-2023031755-A1 | FORMULATIONS, COMPOSITIONS AND METHODS FOR THE DELIVERY OF NEURODEGENERATIVE DRUGS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-03-09 | — | — | WO | claimed |
| EP-4135668-A1 | SOLID ORAL DOSAGE FORM COMPRISING POMALIDOMIDE | Tecnimede, Sociedade Técnico-Medicinal, SA (PT) | 2023-02-22 | — | — | EP | claimed |
| WO-2023002338-A1 | COMPOSITIONS, METHODS OF MAKING AND USING SAME FOR THE DELIVERY OF ULCEROGENIC DRUGS THEREOF | AVACA PHARMA PRIVATE LIMITED (IN) | 2023-01-26 | — | — | WO | claimed |
| WO-2022234139-A1 | LOSARTAN-CONTAINING MICRO TABLET FOR PEDIATRIC APPLICATIONS | Midas Pharma GmbH (DE) | 2022-11-10 | — | — | WO | claimed |
| EP-3135275-B1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | GRINDEKS JSC (LV) | 2020-05-13 | — | — | EP | claimed |
| WO-2019185862-A1 | ORAL DOSAGE FORMS COMPRISING POMALIDOMIDE CRYSTALLINE FORM A | Midas Pharma GmbH (DE) | 2019-10-03 | — | — | WO | claimed |
| EP-3545949-A1 | ORAL DOSAGE FORMS COMPRISING POMALIDOMIDE CRYSTALLINE FORM A | Midas Pharma GmbH (DE) | 2019-10-02 | — | — | EP | claimed |
| US-20180243283-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2018-08-30 | — | — | US | claimed |
| US-9895325-B2 | Tablet composition comprising cinacalcet hydrochloride | SYNTHON B.V. (NL) | 2018-02-20 | — | — | US | claimed |
| WO-2017032870-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2017-03-02 | — | — | WO | claimed |
| EP-3135275-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | Grindeks, A Joint Stock Company (LV) | 2017-03-01 | — | — | EP | claimed |
| EP-3002006-A1 | Pharmaceutical composition capable for the incorporation Febuxostat in the crystalline modifications F10, II, G and A | Bluepharma - Industria Farmacêutica, S.A. (PT) | 2016-04-06 | — | — | EP | claimed |
| WO-2014029953-A1 | HOT MELT EXTRUDED (HME) PHARMACEUTICAL COMPOSITION OF CINACALCET | CIPLA LIMITED (IN) | 2014-02-27 | — | — | WO | claimed |
| EP-0516141-B1 | Pharmaceutical controlled-release composition with bioadhesive properties | RECORDATI CHEM PHARM (CH) | 1996-08-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243283-A1 | PHARMACEUTICAL COMPOSITION CAPABLE OF THE INCORPORATION OF LENALIDOMIDE IN VARIOUS CRYSTALLINE MODIFICATIONS | RPL7, RPL26, PDCD2L | LMNA 1569/4885KDM4E 1761/4885DUSP3 424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.